<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72369">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142842</url>
  </required_header>
  <id_info>
    <org_study_id>1438/QDBYT</org_study_id>
    <nct_id>NCT02142842</nct_id>
  </id_info>
  <brief_title>Autologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee Osteoarthritis</brief_title>
  <official_title>Phase I/II Study of Transplantation of Autologous Adipose Stem Cells and Activated Platelet Rich Plasma in Knee Osteoarthritis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Science Ho Chi Minh City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GeneWorld Co., Ltd. SHTP Ho Chi Minh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Van Hanh Hospital Co., Ho Chi Minh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>115 Hospital, Ho Chi Minh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Science Ho Chi Minh City</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adipose stem cells and platelet rich plasma can regenerate the injured cartilage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is two centers, unblinded, non randomized, phase I/II trial in which the
      patients will be treated with a single dose of autologous stromal vascular cells (SVF) in
      combination with platelet rich plasma (PRP).

      This study aimes to evaluate the clinical efficiency of autologous adipose tissue-derived
      MSC transplantation in patients with confirmed osteoarthritis at grade II and III. Adipose
      tissue is isolated from the belly, and used for extraction of the SVF. The SVF is mixed with
      activated platelet-rich plasma before injection. The clinical efficiencies are evaluated by
      the pain score (VAS), Lysholm score, and MRI findings. SVF is isolated from about 100 mL of
      adipose tissue, and PRP is prepared from 20 mL of peripheral blood. Total injection volume
      will be about 5-10 mL. The total number of SVF to be injected is 1.0 x 10(7) to 5 x 10(7).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from the baseline pain score (VAS) at 6 months</measure>
    <time_frame>6 months, 12 months, 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Lysholm score at 6 months</measure>
    <time_frame>6 months, 12 months, 18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline MRI assessment</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be injected into joints of 16 patients with grade 2, 3  radiographic OA severity with 16 patients as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous adipose tissue stromal vascular fraction and platelet rich plasma</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years and ability to understand the planned treatment.

          -  Idiopathic or secondary osteoarthritis of the knee with grade 2, 3 radiographic
             severity

        Ability and willingness to undergo liposuction

        Exclusion Criteria:

          -  Pregnant women or cognitively impaired adults.

          -  Presence of large meniscal tears (&quot;bucket handle&quot; tears), as detected by clinical
             examination or by magnetic resonance imaging.

          -  Inflammatory or postinfectious arthritis.

          -  More than 5 degrees of varus or valgus deformity.

          -  Kellgren Lawrence grade 4 osteoarthritis in two compartments (the medial or lateral
             compartments of the tibiofemoral joint or the patellofemoral compartment) in persons
             over 60 years of age.

          -  Intraarticular corticosteroid injection within the previous 3 months.

          -  A major neurologic deficit.

          -  Serious medical illness with a life expectancy of less than 1 year.

          -  Prior admission for substance abuse

          -  Body Mass Index (BMI) of 40 kg/m2 or greater

          -  Patient receiving experimental medication or participating in another clinical study
             within 30 days of signing the informed consent

          -  In the opinion of the investigator or the sponsor the patient is unsuitable for
             cellular therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phuc V Pham, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratory of Stem Cell Research and Application, University of Science, VNU-HCM, VN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phuong TB Le, MSc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van Hanh Hospital, Ho Chi Minh city, VN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phu D Nguyen, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>115 Hospital, HCM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho H La, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van Hanh Hospital, Ho Chi Minh city, VN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tung DX Tran, MSc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van Hanh Hospital, Ho Chi Minh city, VN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory of Stem Cell Research and Application, University of Science, Vietnam National University, Ho Chi Minh</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Hanh Hospital, Ho Chi Minh city, VN</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>115 Hospital, Ho Chi Minh city</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Science Ho Chi Minh City</investigator_affiliation>
    <investigator_full_name>Phuc Van Pham</investigator_full_name>
    <investigator_title>Laboratory of Stem Cell Research and Apllication</investigator_title>
  </responsible_party>
  <keyword>Adipose stem cell</keyword>
  <keyword>Platelet rich plasma</keyword>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Injured cartilage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
